Nureca Ltd. (IN:NURECA)
:NURECA
Want to see IN:NURECA full AI Analyst Report?
NURECA Stock Chart & Stats
₹298.85
-₹10.75(-3.41%)
At close: 4:00 PM EST
₹298.85
-₹10.75(-3.41%)
Day’s Range― - ―
52-Week Range₹200.10 - ₹343.60
Previous CloseN/A
Volume68.50K
Average Volume (3M)9.27K
Market Cap
₹2.53B
Enterprise Value₹2.70B
Total Cash (Recent Filing)₹87.40M
Total Debt (Recent Filing)₹53.92M
Price to Earnings (P/E)20.6
Beta1.07
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.73
Shares Outstanding9,541,920
10 Day Avg. Volume526
30 Day Avg. Volume9,266
Financial Highlights & Ratios
PEG Ratio-1.76
Price to Book (P/B)1.13
Price to Sales (P/S)2.00
P/FCF Ratio-9.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong EquityA ~92% equity ratio and favorable debt metrics provide durable financial flexibility. Low leverage reduces refinancing risk, allows room to fund strategic investments or weather cyclical revenue swings, and supports long-term stability despite near-term operating losses.
Product-level Margins / EBITDA RecoveryA moderate gross margin (~38%) and EBITDA improvement point to inherent product profitability. For a branded home-health business, sustainable gross margins enable a path to net profitability if operating expenses are controlled and scale benefits from volumes or channel mix materialize.
Owned Brands & Multichannel ModelOwning Dr Trust and Dr Physio and selling via online and retail channels is a durable business model. Brand ownership supports pricing power, repeat purchases, cross-selling across therapy/monitoring categories, and long-term customer equity versus commodity distributors.
Bears Say
Weak Cash GenerationPersistent negative operating and free cash flow creates a structural funding gap. This limits ability to finance inventory, marketing, and capex internally, increases dependence on external capital, and raises the risk that growth initiatives cannot be funded sustainably over the medium term.
Volatile / Declining RevenueRevenue volatility and a multi-year decline impair predictability and scale economics. In a business that benefits from stable repeat sales, declining top-line reduces ability to absorb fixed costs, weakens bargaining with channels, and makes long-term margin recovery harder to achieve.
Operational InefficienciesNegative EBIT margins and unfavorable free-cash-flow-to-net-income ratios signal structural inefficiencies—cost structure, channel economics, or pricing. Unless fixed, these will persistently depress profitability and limit the company’s ability to convert revenue into sustainable earnings.
Nureca Ltd. News
NURECA FAQ
What was Nureca Ltd.’s price range in the past 12 months?
Nureca Ltd. lowest stock price was ₹200.10 and its highest was ₹343.60 in the past 12 months.
What is Nureca Ltd.’s market cap?
Nureca Ltd.’s market cap is ₹2.53B.
When is Nureca Ltd.’s upcoming earnings report date?
Nureca Ltd.’s upcoming earnings report date is May 21, 2026 which is in 20 days.
How were Nureca Ltd.’s earnings last quarter?
Nureca Ltd. released its earnings results on Jan 17, 2026. The company reported ₹3.734 earnings per share for the quarter, beating the consensus estimate of N/A by ₹3.734.
Is Nureca Ltd. overvalued?
According to Wall Street analysts Nureca Ltd.’s price is currently Overvalued.
Does Nureca Ltd. pay dividends?
Nureca Ltd. pays a Semiannually dividend of ₹3 which represents an annual dividend yield of N/A. See more information on Nureca Ltd. dividends here
What is Nureca Ltd.’s EPS estimate?
Nureca Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nureca Ltd. have?
Nureca Ltd. has 9,541,920 shares outstanding.
What happened to Nureca Ltd.’s price movement after its last earnings report?
Nureca Ltd. reported an EPS of ₹3.734 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.272%.
Which hedge fund is a major shareholder of Nureca Ltd.?
Currently, no hedge funds are holding shares in IN:NURECA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nureca Ltd.
Nureca Limited, a B2C company, engages in the home healthcare and wellness products business in India. It offers chronic disease products, such as nebulizers, blood pressure monitors, finger pulse oximeter, glucose meter, and thermometer; orthopedic products, including massagers, pain monitors, posture correctors, and rehabilitation products; and humidifiers and steamers, personal scales, yoga and exercise, fitness tracking, and dental and personal care products. The company also provides mother and baby care products comprising baby feeding, carry cots, baby skincare, and bottle warmers and steamers; nutritional supplements and weight management products; and ECG, fitness tracker, and smart weighing scale products. Nureca Limited offers its products under Dr Trust, Dr Physio, and Trumom brands. The company sells its products through third party e-commerce players, distributors, and retailers; and through its website, drtrust.in. Nureca Limited was incorporated in 2016 and is based in Chandigarh, India.
Technical Analysis
Advanced Enzyme Technologies Ltd
―
Indoco Remedies Limited
―
Morepen Laboratories Limited
―
Solara Active Pharma Sciences Ltd.
―
Zota Health Care Ltd.
―